GLP-1 Family advanced
Oral Semaglutide Formulation
Oral bioavailability enhancement of semaglutide using SNAC absorption enhancer technology for once-daily oral GLP-1 therapy.
By Encyclopeptide Editorial | 1 min read
semaglutide oral SNAC absorption-enhancer GLP-1
Chemical Identity
| Property | Value |
|---|---|
| Product Name | Rybelsus |
| Active Component | Semaglutide 3, 7, or 14 mg tablets |
| Absorption Enhancer | SNAC (sodium salicylate derivative) |
| Route | Oral, once daily |
Structure
Oral semaglutide uses SNAC to create a localized alkaline pH microenvironment in the stomach, promoting semaglutide absorption through the gastric mucosa via paracellular transport.
Clinical Applications
FDA-approved for type 2 diabetes as Rybelsus (2019). The 14 mg dose reduces HbA1c by 1.0-1.4% and produces weight loss of 4-6 kg.
Pharmacokinetics
- Bioavailability: ~1% (vs 89% SC)
- Tmax: 1 hour (fed state)
- Half-life: ~1 week
- Dosing: Once daily, 30 minutes before first food
Test Your Knowledge
Reinforce what you learned about Oral Semaglutide Formulation with interactive quizzes on Wikipept.
Take a Quiz on Wikipept